Utilization of Key Morphologic and Molecular Prognostic and Predictive Parameters in Endometrial Malignancies: A Survey of Gynecologic Pathologists
- 27 February 2026
- journal article
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 34 (5) , 1134-1145
Abstract
Background: Endometrial carcinoma is a common gynecological malignancy with rising incidence rates. While histopathological staging remains a cornerstone for treatment decisions, its limitations in addressing tumor heterogeneity and molecular complexity have led to the incorporation of molecular subtypes in recent endometrial carcinoma guidelines. Objective: To assess global practice patterns regarding the adoption of genomic profiling, molecular classification, and morphological assessment in endometrial carcinoma, with a focus on recent updates to the International Federation of Gynecology and Obstetrics staging system. Methods: A survey of 68 gynecologic pathologists from Asia, North America, and Europe was conducted, collecting data on their use of morphologic assessments, ancillary immunohistochemical (IHC) tests, and molecular characterization. Results: Our study indicated significant regional variations, with North American and European pathologists more likely to adopt molecular testing, such as mismatch repair (MMR) and p53 IHC, than their Asian counterparts. Despite the growing recognition of molecular subtypes, many pathologists continue to rely on traditional methods, and barriers such as resource limitations and a lack of standardized protocols hinder widespread molecular testing. Conclusion: Our results suggest a need for more uniform adoption of updated guidelines to improve endometrial carcinoma staging accuracy and patient outcomes. Further research and standardized protocols are necessary to ensure the effective and consistent application of molecular biomarkers in clinical practice.Keywords
This publication has 29 references indexed in Scilit:
- FIGO staging of endometrial cancer: 2023International Journal of Gynecology & Obstetrics, 2023
- Relevance of Molecular Profiling in Patients With Low-Grade Endometrial CancerJAMA Network Open, 2022
- Molecular testing for endometrial cancer: An SGO clinical practice statementGynecologic Oncology, 2022
- Radiation Therapy for Endometrial Cancer: An American Society for Radiation Oncology Clinical Practice GuidelinePractical Radiation Oncology, 2022
- Substantial lymphovascular space invasion predicts worse outcomes in early-stage endometrioid endometrial cancerBrachytherapy, 2021
- Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendationsGynecologic Oncology, 2021
- Clinical significance of homologous recombination deficiency score testing in endometrial CancerGynecologic Oncology, 2021
- Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinomaGynecologic Oncology, 2020
- Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancerCancer, 2017
- A clinically applicable molecular-based classification for endometrial cancersBritish Journal of Cancer, 2015